ClinicalTrials.Veeva

Menu

The Study of Sarcopenia and Aging Biomarkers by the Metabolomics

Chang Gung Medical Foundation logo

Chang Gung Medical Foundation

Status

Unknown

Conditions

Aging
Sarcopenia

Treatments

Diagnostic Test: blood and urine sampling

Study type

Observational

Funder types

Other

Identifiers

NCT03121326
201700245B0

Details and patient eligibility

About

With the rapid growth of the global elderly population, the studies of the biomarkers of the sarcopenia and aging are under investigation in different ways. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.

Full description

Metabolomics is the emerging platform technology to address the complexity of a living system. In translational research, metabolomics approaches may enable the detection of multiple disease risk factors and interactions, disease progression, and response of patients to a particular therapy with or without side effects. Metabolomics may provide comprehensive information and improve diagnosis and prognosis which are particularly promising in human complex degenerative diseases. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.

Enrollment

650 estimated patients

Sex

All

Ages

60+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • residents of the Chang Gung Health and Culture Village
  • mostly independent and do not require nursing assistance
  • capable of managing their daily living activities
  • aged ≧ 60

Exclusion criteria

  • None.

Trial contacts and locations

1

Loading...

Central trial contact

Chih-Ming Lin, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems